Study: DermACELL® demonstrates superior clinical outcomes compared to AlloDerm® in breast reconstruction
Go back to Study: DermACELL® demonstrates superior clinical outcomes compared to AlloDerm® in breast reconstruction| NOVADAQ TECHNOLOGIE (NYSE: NVDQ) | Delayed: 8.13 -0.15 (1.81%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $8.28 | 52 Week High | $14.36 | |||
| Open | $8.09 | 52 Week Low | $8.26 | |||
| Day High | $8.18 | P/E | N/A | |||
| Day Low | $7.82 | EPS | $0.00 | |||
| Volume | 7,730,278 | |||||
